[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617708":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":35,"locations":41,"responsibleParty":61,"collaborators":63,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":68,"sex":74,"minAge":25,"maxAge":75,"enrollmentInfo":76,"targetDuration":25,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":44,"whyStopped":25,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of California, Davis","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dopamine Arm","ACTIVE_COMPARATOR","Infants in this group will receive dopamine as their first-line vasopressor. Continuous intravenous dopamine infusion will be initiated at 5 mcg\u002Fkg\u002Fmin and titrated to achieve gestational age appropriate mean arterial blood pressure targets (maximum 20 mcg\u002Fkg\u002Fmin).",[13],"Drug: Dopamine administration",{"label":15,"type":10,"description":16,"interventionNames":17},"Norepinephrine Arm","Infants in this group will receive norepinephrine as their first-line vasopressor. Continuous intravenous norepinephrine infusion initiated at 0.02 mcg\u002Fkg\u002Fmin and titrated to achieve gestational age appropriate mean arterial blood pressure targets (maximum 1 mcg\u002Fkg\u002Fmin).",[18],"Drug: Norepinephrine",[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Dopamine administration","Infants meeting the inclusion criteria who are randomized to dopamine arm will receive dopamine infusion starting at 5 mcg\u002Fkg\u002Fmin, titrated to mean arterial pressure targets based on gestational age, max dose 20 mcg\u002Fkg\u002Fmin.",[9],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Norepinephrine","Infants meeting the inclusion criteria who are randomized to norepinephrine arm will receive norepinephrine infusion starting at 0.02 mcg\u002Fkg\u002Fmin, titrated to mean arterial pressure targets based on gestational age, max dose 1 mcg\u002Fkg\u002Fmin.",[15],[31],{"name":32,"affiliation":33,"role":34},"Deepika Sankaran, MD","UC Davis Health","PRINCIPAL_INVESTIGATOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":25,"email":40},"Solomon P Tatagiri, MBBS","CONTACT","916-734-8672","solomontp@gmail.com",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"UC Davis Children's Hospital","RECRUITING","Sacramento","California","95817","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-121.4944,38.58157,{"lat":54,"lon":53},[57,59],{"name":58,"role":38,"phone":39,"phoneExt":25,"email":40},"Solomon Tatagiri, MBBS",{"name":32,"role":38,"phone":39,"phoneExt":25,"email":60},"dsankaran@health.ucdavis.edu",{"type":62,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR",[64],{"name":65,"class":6},"Children's Miracle Network","100617708","phase-4-dopamine-vs-norepinephrine-for-hypotension-in-neonates-with-pulmonary-hypertension-done-100617708",false,"NCT07322133","Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)","Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial","DONE","Inclusion Criteria:\n\n1. Postmenstrual age \\> 34 6\u002F7 weeks and Postnatal age ≤ 28 days\n2. On respiratory support (Invasive mechanical ventilation, NIPPV, CPAP, HFNC ≥ 2 LPM) and FiO2 ≥ 0.3\n3. Echocardiographic evidence of pulmonary hypertension\n4. Mean arterial pressure below the threshold for gestational age despite a 10-20 mL\u002Fkg fluid bolus\n\nPermissible Comorbidities: CDH, trisomy 21, HIE on hypothermia, PDA, PFO\u002FASD, VSD \\\u003C 2 mm\n\nExclusion Criteria:\n\n1. Gestational age \\\u003C 32 weeks\n2. Severe hypoxic respiratory failure (OI \\> 35 or SpO2 \\\u003C 75% on 100% FiO2 for \\> 60 minutes)\n3. Lethal anomalies (e.g., trisomy 13 or 18)\n4. Complex congenital heart disease beyond specified criteria","ALL","28 Days",{"count":77,"type":78},30,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.",[84,85,86],"Hypotension and Shock","Pulmonary Hypertension of the Newborn (PPHN)","Hypoxemic Respiratory Failure",[88,89,90],"Pulmonary Hypertension","Systemic Hypotension","Vasopressor","2026-02-05",{"date":93,"type":94},"2026-02-10","ACTUAL",{"date":96,"type":78},"2026-06-01",{"date":98,"type":78},"2028-01-31",{"name":5,"class":6},1]